How-to guides

Eloralintide: Metabolic / Fat Loss research guide

Not medical advice. Eloralintide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

What Eloralintide is

Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist engineered for once-weekly dosing, with an amylin-pathway appetite mechanism complementary to GLP-1 receptor agonists.

One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.

Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology.

Research contexts

Peer-reviewed literature typically discusses Eloralintide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.

Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.

Typical study contexts

Incretin pathways, food intake, and glucose homeostasis in rodent models and validated assays.

Clinical trial literature exists for some drug-class molecules; those trials are distinct from research-grade catalogue use.

Peer-reviewed preclinical work sometimes describes experiments that track whether selective amylin receptor agonist — preferentially activates human AMY1R over the calcitonin receptor and AMY3R in vitro

Peer-reviewed preclinical work sometimes describes experiments that track whether c20 fatty-diacid / di-γ-glutamate acylation enables albumin binding for once-weekly subcutaneous dosing

Peer-reviewed preclinical work sometimes describes experiments that track whether cys2–Cys7 methylene-thioacetal bridge stabilises the amylin scaffold against degradation

Peer-reviewed preclinical work sometimes describes experiments that track whether reduces caloric intake through amylin-pathway satiety signalling, a mechanism distinct from GLP-1

Why Metabolic / Fat Loss research matters

Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.

Mechanisms (technical review)

Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.

Selective amylin receptor agonist — preferentially activates human AMY1R over the calcitonin receptor and AMY3R in vitro

C20 fatty-diacid / di-γ-glutamate acylation enables albumin binding for once-weekly subcutaneous dosing

Cys2–Cys7 methylene-thioacetal bridge stabilises the amylin scaffold against degradation

Reduces caloric intake through amylin-pathway satiety signalling, a mechanism distinct from GLP-1

Phase 1 proof-of-concept: well tolerated with minimal gastrointestinal adverse events

Reported Phase 2 obesity programme: clinically meaningful weight reduction with favourable tolerability

Lab handling & preparation

Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.

Research dosing context: Literature typically discusses Reported only as published research context — not a recommendation · Once-weekly subcutaneous injection in published research · Eloralintide is protracted for once-weekly subcutaneous administration and was titrated over several weeks in the published clinical programme. Exact escalation schedules are model- and study-specific and are not reproduced here as a protocol. Research use only — not for human use.

Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.

Common Questions People Are Asking

What is eloralintide and how does it work?

Eloralintide (LY3841136) is a selective, long-acting amylin receptor agonist. It engages the amylin satiety pathway — hindbrain and hypothalamic appetite circuits — to reduce caloric intake, and in vitro it preferentially activates the human AMY1R receptor over the calcitonin receptor and AMY3R subtype. A lipid side chain at Lys26 (two γ-glutamate residues plus a C20 fatty diacid) binds serum albumin to extend its duration of action for once-weekly research dosing.

How is eloralintide different from cagrilintide?

Both are long-acting amylin analogues, but cagrilintide is a non-selective agonist across the amylin receptor family and the calcitonin receptor, whereas eloralintide is reported to be selective — preferentially activating the AMY1R amylin receptor. That selectivity is the main design difference between the two research peptides.

How is eloralintide different from a GLP-1 agonist?

GLP-1 agonists such as semaglutide activate the GLP-1 (incretin) receptor. Eloralintide activates the amylin receptor pathway. The two systems are distinct satiety circuits, which is why eloralintide has been studied both on its own and as a complement to incretin therapy.

What does the research on eloralintide actually show?

Published Phase 1 proof-of-concept research reported that once-weekly eloralintide was well tolerated with minimal gastrointestinal adverse events, and a subsequently reported Phase 2 obesity programme described clinically meaningful body-weight reduction with favourable tolerability. These are descriptive research findings for an investigational compound, not outcomes promised for any use of this research-grade material.

Is eloralintide approved or legal?

Eloralintide is an investigational compound (LY3841136) and is not an approved medicine in any jurisdiction. The material supplied here is unapproved, research-grade laboratory material sold strictly for in-vitro and preclinical research use only — not for human use.

How is eloralintide reconstituted and stored?

Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water by directing it down the vial wall rather than onto the powder, then swirl gently — do not shake. After reconstitution, refrigerate at 1–6 °C and protect from light. Avoid repeated freeze–thaw cycles, which can damage the fatty-acid tail.

Is this page medical advice? Can I use Eloralintide for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Eloralintide specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Eloralintide.

Retatrutide - companion guide

Semaglutide - companion guide

Tirzepatide - companion guide

Cagrilintide - companion guide

Scientific sources & further reading

Primary literature and registries for Eloralintide, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Eloralintide

ClinicalTrials.gov: registered studies on Eloralintide

Eloralintide: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: Eloralintide, LY3841136, Selective Amylin Receptor Agonist, Long-Acting Amylin Analogue

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.